Ligand Pharm
(NQ:
LGND
)
103.82
+0.20 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ligand Pharm
< Previous
1
2
3
Next >
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 20, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports Second Quarter 2024 Financial Results
August 06, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
July 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
5 Best Short-Term Stocks to Consider Investing In
July 10, 2024
Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading.
Via
MarketBeat
Ligand to Acquire APEIRON Biologics AG for $100 Million
July 08, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
July 01, 2024
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board
From
Lifecore Biomedical, Inc.
Via
GlobeNewswire
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
June 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
June 18, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Participate in Upcoming Investor Conferences
May 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Reports First Quarter 2024 Financial Results
May 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
May 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
April 23, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
April 08, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
April 03, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Making Surprising Moves in Tuesday Session
February 27, 2024
Via
Investor Brand Network
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
February 22, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
February 16, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
January 05, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
December 12, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
December 06, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
December 01, 2023
From
Palvella Therapeutics
Via
GlobeNewswire
Ligand Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
November 01, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ligand To Report Third Quarter 2023 Financial Results On November 8
October 25, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
October 18, 2023
From
Ovid Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.